Follow The Filings

CRBU Caribou Biosciences Inc.

Health Care, filed as CARIBOU BIOSCIENCES INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

  • 1 Owner
  • Max 0.0%
  • $1.1M

Who owns this now

Largest portfolio weights among holders, up to 0.0% (Lee Ainslie, Maverick Capital). Not free-float ownership.

  1. Lee Ainslie 0.01%

Who owns CRBU

Sorted by value, long equity only, as of 2026 Q2.

History
Lee Ainslie, Maverick Capital 0.01% Hold 652,542 $1.1M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by CRBU's executives, directors and 10% owners in the last 12 months, from their Form 4s

All CRBU insider trades
  • None no insider bought on the open market
  • $12K sold by 1 insider outside a trading plan
  • None no planned (10b5-1) sales
  1. Timothy P Kelly Chief Technology Officer
    Sale
    $12K 6,228 shares at $1.93 7.8% of stake
    Traded Feb 25 Filed Feb 27
    ↗

Also filed in the last 12 months, not counted as buying or selling: 6 stock grants and 4 sales to cover taxes.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
8-K 2.05,5.02,7.01,8.01,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G — Filing Doc
8-K 5.07,9.01 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
DEFA14A Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 2.02,7.01,8.01,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 8.01 Filing Doc
8-K 5.07,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
DEFA14A Filing Doc

Source: SEC EDGAR submissions, updated 12 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $34.48M $9.99M $11.16M
Net income -$102.07M -$149.1M -$148.12M
Net margin * -296.1% -1491.9% -1327.4%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $338.84M $219.38M $145.23M
Total non-current assets * $93.37M $93.94M $30.14M
Total assets $432.21M $313.31M $175.37M
Total current liabilities $28.3M $30.65M $25.41M
Total non-current liabilities * $35.51M $29.71M $27.78M
Total equity $368.4M $252.95M $122.18M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$93.29M -$138.2M -$110.99M
Cash from investing -$68.18M $86.61M $102.24M
Cash from financing $154.3M $16.72M $4.82M
Net change in cash -$7.18M -$34.87M -$3.93M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.